Everything You Need To Know About PARP Inhibitor

PARP Inhibitor

PARP Inhibitor are a relatively new class of drugs that have been gaining attention for their ability to treat cancer. PARP, or poly (ADP-ribose) polymerase, is an enzyme that repairs DNA damage within cells.

When a Olaparib is introduced into the body, it prevents the enzyme from repairing damaged DNA, which can ultimately lead to the death of cancerous cells. In this article, we will explore the science behind Olaparib, their role in cancer treatment, and some of the potential side effects associated with their use.

The PARP Inhibitor Market of poly ADP-ribose polymerase (PARP) was estimated at US$ 887.7 million in 2018 and is anticipated to grow at a CAGR of 32.4% during the projected period (2019–2027).

The Science Behind PARP Inhibitors

In order to understand how Olaparib work, it is helpful to have a basic understanding of how DNA is repaired within cells. When a cell experiences damage to its DNA, it activates a process called the DNA damage response.

This process involves a complex network of proteins and enzymes that work together to repair the damaged DNA. One key player in this process is the PARP enzyme. PARP binds to the damaged DNA and begins repairing it by adding chains of ADP-ribose molecules to the surrounding proteins.

The increase in the incidence or prevalence of cancer and the rising elderly population worldwide are both contributing to the rapid expansion of the global PD-1 and PD-L1 Inhibitor Market.

However, Olaparib prevent this repair process from taking place. By blocking the PARP enzyme, the damaged DNA is left unrepaired, which can ultimately lead to the death of the cell. While this may seem like a dangerous approach, it is actually quite targeted.

Cancer cells are particularly vulnerable to this type of damage because they often have defects in their DNA repair mechanisms to begin with. This makes them more reliant on the PARP pathway for repair, and therefore more susceptible to Olaparib -induced cell death.

PARP Inhibitor are a promising new class of drugs that are being used to treat a wide range of cancers. By targeting the PARP enzyme, these drugs prevent the repair of damaged DNA, ultimately leading to the death of cancerous cells. While Olaparib are generally well-tolerated, they can cause side effects that need.